NEW YORK, NY / ACCESSWIRE / December 13, 2018 / U.S. equities closed higher on Wednesday amidst renewed hopes over the U.S.-China trade talks. According to a report in Wall Street Journal, China is working on a plan to expand their access to foreign companies that will support the U.S.-China trade relations, and will replace the Made in China 2025 plan. The Dow Jones Industrial Average gained 0.64 percent to close at 24,527.27, while the S&P 500 Index increased 0.54 percent to close at 2,651.07. The Nasdaq Composite Index climbed 0.95 percent to close at 7,098.31.
The Market Edge Initiates Coverage on:
Intercept Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc.
Intercept Pharmaceuticals' stock jumped 5.84% Wednesday, to close the day at $110.70. The stock recorded a trading volume of 445,450 shares, which was below its three months average volume of 456,552 shares. In the last year, Intercept Pharmaceuticals' shares have traded in a range of 51.05 - 133.74. The share price has gained 116.85% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $103.58 is above its 200-day moving average of $100.65. Shares of Intercept Pharmaceuticals have gained roughly 9.85 percent in the past month and are up 89.49 percent year-to-date.
Access The Market Edge's Intercept Pharmaceuticals, Inc. ResearchReport:
On Wednesday, shares of Ultragenyx Pharmaceutical recorded a trading volume of 372,160 shares, which was below the three months average volume of 550,375 shares. The stock ended the day 3.11% higher at $47.13. The share price has fallen 48.2% from its 52 week high with a 52 week trading range of 41.67 - 90.98. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $52.19 is below its 200-day moving average of $71.99. Shares of Ultragenyx Pharmaceutical have fallen roughly 4.01 percent in the past month and are up 1.62 percent year-to-date.
Access The Market Edge's Ultragenyx Pharmaceutical Inc. ResearchReport:
The Market Edge
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
The Market Edge has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of MarketEdgeReport.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. MarketEdgeReport.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.marketedgereport.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
The Market Edge, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: The Market Edge